MAP2K7 and neuroblastoma: This presents a therapeutic window for SHP2 inhibitors not appreciated with MEK inhibitors that, when also considering unwanted MEK inhibitor-specific mTORC2 feedback, highlights a possible and particular utility of SHP2 inhibitors in a subset of NB (type 2).